Merck Reports Phase 3 KEYNOTE-716 Results for Adjuvant Keytruda in Stage II Melanoma

Merck today announced results from the Phase 3 KEYNOTE-716 trial evaluating adjuvant Keytruda (pembrolizumab) in patients with resected Stage IIB or IIC melanoma. The trial met its primary endpoint, demonstrating a significant improvement in recurrence-free survival with Keytruda, with a 35% reduction in the risk of disease recurrence or death. These results led to FDA approval of Keytruda as adjuvant therapy for Stage IIB/IIC melanoma.